Evidence map›Paper›PMID 42193935›Full record

ReviewCells2026

Pleiotrophin in Mammary Gland Development and Breast Cancer: A Comprehensive Review of the Evidence.

Arianna S Gholami, Ciara N Walsh, Jean McBryan

Abstract readReview
In one paragraph

Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Arianna S GholamiSchool of Medicine, RCSI University of Medicine and Health Sciences, 123 St Stephen's Green, D02 YN77 Dublin, Ireland.
Ciara N WalshDepartment Surgery, RCSI University of Medicine and Health Sciences, Beaumont Hospital, D09 YD60 Dublin, Ireland.ORCID 0000-0002-7873-5627
Jean McBryanDepartment Surgery, RCSI University of Medicine and Health Sciences, Beaumont Hospital, D09 YD60 Dublin, Ireland.ORCID 0000-0002-7568-2208

Funding

Beaumont Hospital n/aIrish Cancer Society CRSD24MCB
6 · The paper itself

Abstract

Pleiotrophin (PTN), a heparin-binding growth factor with potent mitogenic and angiogenic activity, has emerged as a key regulator of mammary gland biology and a potential driver of breast cancer progression. This review integrates current evidence on PTN's roles from normal mammary development, where it can delay ductal outgrowth, to triple negative breast cancer, where it promotes lung metastasis and correlates with poor survival. Though frequently reported as being overexpressed in breast cancer, the published data indicates that

Indexed as

Breast NeoplasmsCarrier ProteinsCytokinesMammary Glands, HumanAnimalsFemaleHumansTumor MicroenvironmentCarrier ProteinsCytokinespleiotrophinangiogenesisbiomarkerbreast cancerdevelopmentdrug resistancepleiotrophinserumtranscriptomics

Identifiers

PMID42193935
PMCPMC13204032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.